On March 11, 2025, Mineralys Therapeutics entered into an underwriting agreement to sell 12,962,962 shares of common stock at $13.50 per share, expecting to raise approximately $164.2 million, or $188.8 million if additional shares are purchased. The offering is set to close on March 13, 2025, subject to customary conditions.